National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting, 60905-60906 [2024-16614]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 145 / Monday, July 29, 2024 / Notices
60905
Current Org Chart • ONC
[FR Doc. 2024–16571 Filed 7–25–24; 8:45 am]
BILLING CODE 4150–24–C
ddrumheller on DSK120RN23PROD with NOTICES1
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
VerDate Sep<11>2014
18:51 Jul 26, 2024
Jkt 262001
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Initial Review Group; Digestive Diseases and
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
Nutrition C Study Section Mentored Career
Development Applications in Digestive
Diseases and Nutrition.
Date: October 9–11, 2024.
Time: 5:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
NIDDK, Democracy II, Suite 7000A, 6707
Democracy Boulevard, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Peter J. Kozel, Ph.D.,
Scientific Review Officer, National Institute
of Diabetes and Digestive and Kidney,
National Institute of Health, 6707 Democracy
Boulevard, Rm. 7009, Bethesda, MD 20892–
5452, (301) 594–4721, kozelp@mail.nih.gov.
E:\FR\FM\29JYN1.SGM
29JYN1
EN29JY24.007</GPH>
Future Org Chart - ONC
60906
Federal Register / Vol. 89, No. 145 / Monday, July 29, 2024 / Notices
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: July 24, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–16614 Filed 7–26–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Adeno-Associated
Virus Vector-Mediated Gene Delivery
of Human Aquaporin-1 To Prevent
Radiation-Induced Salivary
Hypofunction
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institute of
Diabetes and Digestive and Kidney
Disease and National Institute of Dental
and Craniofacial Research, institutes of
the National Institutes of Health,
Department of Health and Human
Services, are contemplating the grant of
an Exclusive Patent License to practice
the inventions embodied in the
Australian, Brazilian, Canadian,
Chinese, European, Hong Kong, Israeli,
Japanese, South Korean, Mexican,
Malaysian, New Zealand, Philippines,
Singapore, United States, and South
African Applications listed in the
Supplementary Information section of
this notice to MeiraGTx, LLC, located in
New York City, New York, USA.
DATES: Only written comments and/or
applications for a license that are
received by the National Institute of
Diabetes and Digestive and Kidney
Disease’s Technology Advancement
Office on or before August 13, 2024 will
be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: Vladimir Knezevic, MD,
(Senior) Advisor for Commercial
Evaluation, Technology Advancement
Office, Building 12A, Room 3011,
Bethesda, MD 20817–5632 (for business
mail), Telephone: (301) 435–5560;
Email: vlado.knezevic@nih.gov.
SUPPLEMENTARY INFORMATION:
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
18:51 Jul 26, 2024
Jkt 262001
Intellectual Property
I. ARIPO Patent Application AP/P/
2024/015557 filed on February 28, 2024,
entitled ‘‘AQP1 Gene Therapy To
Prevent Radiation-Induced Salivary
Hypofunction’’ (HHS Reference Number
E–129–2021–0–AP–01).
II. Australian Patent Application
2022325158 filed on February 26, 2024,
entitled ‘‘AQP1 Gene Therapy To
Prevent Radiation-Induced Salivary
Hypofunction’’ (HHS Reference Number
E–129–2021–0–AU–01).
III. Brazilian Patent Application
BR112024002194–7 filed on February 7,
2024, entitled ‘‘AQP1 Gene Therapy To
Prevent Radiation-Induced Salivary
Hypofunction’’ (HHS Reference Number
E–129–2021–0–BR–01).
IV. Canadian Patent Application
3227584 filed on January 31, 2024,
entitled ‘‘AQP1 Gene Therapy To
Prevent Radiation-Induced Salivary
Hypofunction’’ (HHS Reference Number
E–129–2021–0–CA–01).
V. Chinese Patent Application
202280058429.9 filed on February 27,
2024, entitled ‘‘AQP1 Gene Therapy To
Prevent Radiation-Induced Salivary
Hypofunction’’ (HHS Reference Number
E–129–2021–0–CN–01).
VI. Eurasian Patent Application
202490372 filed on March 1, 2024,
entitled ‘‘AQP1 Gene Therapy To
Prevent Radiation-Induced Salivary
Hypofunction’’ (HHS Reference Number
E–129–2021–0–EA–01).
VII. European Patent Application
22786210.9 filed March 1, 2024, entitled
‘‘AQP1 Gene Therapy To Prevent
Radiation-Induced Salivary
Hypofunction’’ (HHS Reference Number
E–129–2021–0–EP–01).
VIII. Hong Kong Patent Application
entitled ‘‘AQP1 Gene Therapy To
Prevent Radiation-Induced Salivary
Hypofunction’’ (HHS Reference Number
E–129–2021–0–HK–01) with the priority
filing date of August 4, 2021.
IX. Israeli Patent Application 310485
filed on January 29, 2024, entitled
‘‘AQP1 Gene Therapy To Prevent
Radiation-Induced Salivary
Hypofunction’’ (HHS Reference Number
E–129–2021–0–IL–01).
X. Japanese Patent Application 2024–
506727 filed on February 2, 2024,
entitled ‘‘AQP1 Gene Therapy To
Prevent Radiation-Induced Salivary
Hypofunction’’ (HHS Reference Number
E–129–2021–0–JP–01).
XI. South Korean Patent Application
10–2024–7007179 filed on February 29,
2024, published as 10–2024–0049295 on
April 16, 2024, entitled ‘‘AQP1 Gene
Therapy To Prevent Radiation-Induced
Salivary Hypofunction’’ (HHS Reference
Number E–129–2021–0–KR–01).
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
XII. Mexican Patent Application MX/
a/2024/001577 filed on February 1,
2024, entitled ‘‘AQP1 Gene Therapy To
Prevent Radiation-Induced Salivary
Hypofunction’’ (HHS Reference Number
E–129–2021–0–MX–01).
XIII. Malaysian Patent Application
PI2024000751 filed on February 2, 2024,
entitled ‘‘AQP1 Gene Therapy To
Prevent Radiation-Induced Salivary
Hypofunction’’ (HHS Reference Number
E–129–2021–0–MY–01).
XIV. New Zealand Patent Application
808619 filed on February 26, 2024,
entitled ‘‘AQP1 Gene Therapy To
Prevent Radiation-Induced Salivary
Hypofunction’’ (HHS Reference Number
E–129–2021–0–NZ–01).
XV. Philippines Patent Application 1–
2024–550312 filed on February 2, 2024,
entitled ‘‘AQP1 Gene Therapy To
Prevent Radiation-Induced Salivary
Hypofunction’’ (HHS Reference Number
E–129–2021–0–PH–01).
XVI. Singapore Patent Application
11202400787X filed on February 2,
2024, entitled ‘‘AQP1 Gene Therapy To
Prevent Radiation-Induced Salivary
Hypofunction’’ (HHS Reference Number
E–129–2021–0–SG–01).
XVII. United States Patent
Application 18/294,048 filed on January
31, 2024, entitled ‘‘AQP1 Gene Therapy
To Prevent Radiation-Induced Salivary
Hypofunction’’ (HHS Reference Number
E–129–2021–0–US–02).
XVIII. South African Patent
Application 2024/01677, filed on
February 27, 2024, entitled ‘‘AQP1 Gene
Therapy To Prevent Radiation-Induced
Salivary Hypofunction’’ (HHS Reference
Number E–129–2021–0–ZA–01).
The patent rights for these inventions
have been assigned to the Government
of the United States of America. The
prospective exclusive license territory
may be worldwide and in fields of use
that may be limited to use of adenoassociated virus 2 vector-mediated gene
delivery of human aquaporin-1 for the
prevention of radiation-induced
xerostomia (‘dry mouth’ syndrome).
The above-listed patent portfolio
covers inventions directed to gene
therapy and specifically, expression
vector and therapeutic method of using
such vector in the prevention of
radiation-induced xerostomia.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty-bearing. The prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
E:\FR\FM\29JYN1.SGM
29JYN1
]]>Agencies
[Federal Register Volume 89, Number 145 (Monday, July 29, 2024)]
[Notices]
[Pages 60905-60906]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-16614]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Initial Review Group; Digestive Diseases and
Nutrition C Study Section Mentored Career Development Applications
in Digestive Diseases and Nutrition.
Date: October 9-11, 2024.
Time: 5:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, NIDDK, Democracy II, Suite
7000A, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Peter J. Kozel, Ph.D., Scientific Review
Officer, National Institute of Diabetes and Digestive and Kidney,
National Institute of Health, 6707 Democracy Boulevard, Rm. 7009,
Bethesda, MD 20892-5452, (301) 594-4721, [email protected].
[[Page 60906]]
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: July 24, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-16614 Filed 7-26-24; 8:45 am]
BILLING CODE 4140-01-P
